Titlebook: Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics; Jianguo Tao,Eduardo Sotomayor Book 2012 Springer Science+Busine

高腳酒杯

Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy,n several crucial molecular pathways that support the proliferative potential of CLL. Since molecules in these pathways can contribute to proliferation, survival and chemoresistance of CLL, they are potentially useful therapeutic targets. We discussed promising methods that have been developed to ta

Palliation

Grasping

Myelodysplastic Syndromes,0 it now approaches 75 per 100,000 (Cogle et al. 2011). Men are affected at a somewhat higher rate than women. There is no apparent geographical bias to the distribution of MDS; on an age-adjusted basis, the incidence is similar throughout the world, although it should be noted that these studies we

triptans

mendacity

Hippocampus

Epigenetic Regulation and Therapy in Lymphoid Malignancies,cologically reversible, they have been regarded as optimal targets for what is now known as epigenetic therapy. In this review, we will discuss our current understanding of normal epigenetic processes, outline our knowledge of epigenetic alterations, discuss advances in the understanding of post-tra

lymphedema

B Cell Growth, Differentiation and Malignancies,teria, viruses and other foreign insults to the human body. Each B cell makes only one distinct immunoglobulin which recognizes a cognate antigen. It is estimated that B cells in the human body can produce as many as 10. different antibodies. Thus, each B cell must undergo a series of differentiatio

難理解

Follicular Lymphoma: Recent Advances,astic follicles that resemble the normal GC. Normal GCB-cells do not express the anti-apoptotic protein B-cell leukemia/lymphoma 2 (BCL2) and they readily undergo apoptosis if they do not have a high affinity antigen receptor that will transmit survival signals on recognition of the antigen. The vas

absorbed

Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy,r symptoms for a long period of time and require no treatment. However, malignant progression of CLL strikes indefinitely in some patients, and such CLL responds poorly to conventional chemotherapies and will eventually acquire chemoresistance. Currently, no efficient therapeutic options are availab

overwrought